Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opexa Therapeutics has completed its previously announced public offering of 3.5 million shares of common stock at a price to the public of $2 per share and 3.5 million series E warrants to purchase shares of common stock exercisable at $2 per share at a price of $0.15 per warrant.
Subscribe to our email newsletter
The company has granted a 30-day option to the underwriters to purchase up to an additional 15% of the offering to cover over-allotments, and the underwriters have exercised the over-allotment option for 525,000 series E warrants. The net proceeds to the company of the offering, which included the exercise in full of the over-allotment option for the warrants, were $6.8 million after payment of underwriting discounts and commissions, but excluding estimated offering expenses.